Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Gilteritinib

Known as: 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide 
An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
BACKGROUND Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3… Expand
Is this relevant?
2019
2019
Gilteritinib (Xospata®) is an orally available small molecule receptor tyrosine kinase inhibitor developed by Astellas Pharma in… Expand
Is this relevant?
2019
2019
Introduction: Gilteritinib is a potent/selective oral inhibitor of FMS-like tyrosine kinase 3 (FLT3). Based upon interim analysis… Expand
Is this relevant?
2018
2018
Introduction: Gilteritinib is a novel, potent, highly-selective oral fms-like tyrosine kinase 3 (FLT3)/AXL inhibitor. Once-daily… Expand
Is this relevant?
2018
2018
Background: Gilteritinib, a highly selective, potent FLT3/AXL inhibitor, showed antileukemic activity with favorable tolerability… Expand
Is this relevant?
Highly Cited
2017
Highly Cited
2017
Background Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations are common in acute myeloid leukemia (AML… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 4
Is this relevant?
Highly Cited
2017
Highly Cited
2017
To the editor: FLT3-activating mutations are one of the most frequent genetic aberrations in acute myeloid leukemia (AML).[1][1… Expand
Is this relevant?
2017
2017
SummaryAdvances in the understanding of the molecular basis for acute myeloid leukemia (AML) have generated new potential targets… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
Background: Gilteritinib (ASP2215) is a novel, highly selective, potent oral FLT3/AXL inhibitor with preclinical activity against… Expand
Is this relevant?
Highly Cited
2016
Highly Cited
2016
7008Background: We investigated the clinical activity, PK, safety and resistance mechanisms to single-agent crenolanib patients… Expand
Is this relevant?